Published in Mol Cancer Ther on October 01, 2003
The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal (2009) 2.43
Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxid Redox Signal (2008) 1.58
Going ape as an approach to cancer therapeutics. Antioxid Redox Signal (2009) 1.25
Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids. Mol Pharmacol (2007) 1.23
DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med Chem (2008) 1.17
Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions. DNA Repair (Amst) (2009) 1.07
Distinct roles of Ape1 protein in the repair of DNA damage induced by ionizing radiation or bleomycin. J Biol Chem (2010) 1.06
ASCIZ regulates lesion-specific Rad51 focus formation and apoptosis after methylating DNA damage. EMBO J (2005) 1.05
Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase. Biochem Pharmacol (2010) 1.02
Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair. Cell Death Dis (2012) 0.90
Identification and characterization of human apurinic/apyrimidinic endonuclease-1 inhibitors. Biochemistry (2012) 0.88
Direct detection and quantification of abasic sites for in vivo studies of DNA damage and repair. Nucl Med Biol (2009) 0.87
Conformational transitions in human AP endonuclease 1 and its active site mutant during abasic site repair. Biochemistry (2010) 0.85
Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs. Future Med Chem (2012) 0.83
Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide. Clin Exp Med (2012) 0.83
Evidence for base excision repair processing of DNA interstrand crosslinks. Mutat Res (2012) 0.80
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest New Drugs (2012) 0.79
Covalent adduct formation between the antihypertensive drug hydralazine and abasic sites in double- and single-stranded DNA. Chem Res Toxicol (2014) 0.77
Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells. Cancer Biol Ther (2015) 0.76
Developing an in silico model of the modulation of base excision repair using methoxyamine for more targeted cancer therapeutics. IET Syst Biol (2013) 0.75
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant (2005) 2.82
Metabolic regulation by the mitochondrial phosphatase PTPMT1 is required for hematopoietic stem cell differentiation. Cell Stem Cell (2013) 2.12
Targeted modulation of MGMT: clinical implications. Clin Cancer Res (2006) 1.83
DNA repair defects in stem cell function and aging. Annu Rev Med (2005) 1.74
Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. J Mol Med (Berl) (2008) 1.72
Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol (2006) 1.63
Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling. Hypertension (2009) 1.59
Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice. Hypertension (2010) 1.57
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol (2009) 1.56
Disruption of mindin exacerbates cardiac hypertrophy and fibrosis. J Mol Med (Berl) (2012) 1.48
Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. J Clin Invest (2012) 1.46
Humans accumulate microsatellite instability with acquired loss of MLH1 protein in hematopoietic stem and progenitor cells as a function of age. Blood (2012) 1.45
Repopulating defect of mismatch repair-deficient hematopoietic stem cells. Blood (2003) 1.44
A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia. Leuk Res (2003) 1.39
Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells. J Exp Med (2011) 1.37
The role of DNA damage repair in aging of adult stem cells. Nucleic Acids Res (2007) 1.35
Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs (2004) 1.27
In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J Clin Invest (2003) 1.26
Synergistic actions of hematopoietic and mesenchymal stem/progenitor cells in vascularizing bioengineered tissues. PLoS One (2008) 1.26
Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res (2002) 1.25
The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol (2009) 1.19
Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry (2010) 1.16
Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol (2010) 1.15
Puerarin attenuates high-glucose-and diabetes-induced vascular smooth muscle cell proliferation by blocking PKCbeta2/Rac1-dependent signaling. Free Radic Biol Med (2009) 1.14
Interferon regulatory factor 3 is a negative regulator of pathological cardiac hypertrophy. Basic Res Cardiol (2013) 1.10
Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies. Clin Cancer Res (2003) 1.09
LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling. Hypertension (2009) 1.08
Thermal stability and inactivation of hepatitis C virus grown in cell culture. Virol J (2010) 1.07
Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol (2010) 1.06
Cytokines, including stem cell factor alone, enhance lentiviral transduction in nondividing human LTCIC and NOD/SCID repopulating cells. Mol Ther (2003) 1.06
Role of the Legionella pneumophila rtxA gene in amoebae. Microbiology (2002) 1.06
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res (2005) 1.05
Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. Antiviral Res (2009) 1.04
Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIalpha. Clin Cancer Res (2007) 1.02
Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway. J Cell Mol Med (2008) 1.00
Allicin protects against cardiac hypertrophy and fibrosis via attenuating reactive oxygen species-dependent signaling pathways. J Nutr Biochem (2010) 0.99
Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics. Am J Hematol (2009) 0.98
Analysis of noise in quorum sensing. OMICS (2003) 0.98
G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation. J Biol Chem (2008) 0.98
Cancer gene therapy: scientific basis. Annu Rev Med (2002) 0.98
Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379. Mol Cell Biol (2008) 0.98
Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Mol Ther (2002) 0.98
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts. Biol Blood Marrow Transplant (2011) 0.97
Matricellular protein CCN3 mitigates abdominal aortic aneurysm. J Clin Invest (2016) 0.96
Recurrence in giant cell tumour of bone: imaging features and risk factors. Radiol Med (2012) 0.94
Inactivated MGMT by O6-benzylguanine is associated with prolonged G2/M arrest in cancer cells treated with BCNU. Oncogene (2005) 0.94
Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res (2008) 0.94
Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling. Hypertension (2010) 0.94
Intrafamilial viral transmission is not the main cause of the high prevalence of hepatic C virus infection in a village, Putian county, China. J Clin Virol (2011) 0.93
Transcriptional profiling of human mesenchymal stem cells transduced with reporter genes for imaging. Physiol Genomics (2008) 0.93
Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients. Antivir Ther (2010) 0.92
Cellular FLICE-inhibitory protein protects against cardiac remodelling after myocardial infarction. Basic Res Cardiol (2011) 0.91
Identification of 6-benzylthioinosine as a myeloid leukemia differentiation-inducing compound. Cancer Res (2008) 0.91
Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients. Mol Ther (2003) 0.90
Arsenic induces the expressions of angiogenesis-related factors through PI3K and MAPK pathways in SV-HUC-1 human uroepithelial cells. Toxicol Lett (2013) 0.90
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res (2004) 0.90
Exonuclease 1 is a critical mediator of survival during DNA double strand break repair in nonquiescent hematopoietic stem and progenitor cells. Stem Cells (2014) 0.89
Cellular repressor of E1A-stimulated genes attenuates cardiac hypertrophy and fibrosis. J Cell Mol Med (2008) 0.88
N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells. Leuk Lymphoma (2005) 0.88
Connectivity map analysis of nonsense-mediated decay-positive BMPR2-related hereditary pulmonary arterial hypertension provides insights into disease penetrance. Am J Respir Cell Mol Biol (2012) 0.88
Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia. Clin Lymphoma Myeloma Leuk (2010) 0.87
Direct detection and quantification of abasic sites for in vivo studies of DNA damage and repair. Nucl Med Biol (2009) 0.87
Imaging stem cell implant for cellular-based therapies. Exp Biol Med (Maywood) (2008) 0.87
A general excimer signaling approach for aptamer sensors. Biosens Bioelectron (2010) 0.87
Bioluminescence imaging of hematopoietic stem cell repopulation in murine models. Methods Mol Biol (2008) 0.87
O6-benzylguanine and BCNU in multiple myeloma: a phase II trial. Cancer Chemother Pharmacol (2007) 0.86
Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling. J Cell Biochem (2010) 0.86
In vivo powering of pacemaker by breathing-driven implanted triboelectric nanogenerator. Adv Mater (2014) 0.86
Chymotrypsin B cached in rat liver lysosomes and involved in apoptotic regulation through a mitochondrial pathway. J Biol Chem (2008) 0.85
An intrinsic BM hematopoietic niche occupancy defect of HSC in scid mice facilitates exogenous HSC engraftment. Blood (2011) 0.85
Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signalling. Br J Pharmacol (2010) 0.85
Limited lentiviral transgene expression with increasing copy number in an MGMT selection model: lack of copy number selection by drug treatment. Mol Ther (2004) 0.85
Oxidative stress and MAPK involved into ATF2 expression in immortalized human urothelial cells treated by arsenic. Arch Toxicol (2013) 0.85
Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer. Cancer Res (2002) 0.84
Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication. J Virol (2008) 0.84
Disruption of tumor necrosis factor receptor associated factor 5 exacerbates pressure overload cardiac hypertrophy and fibrosis. J Cell Biochem (2014) 0.84
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. Clin Cancer Res (2004) 0.84
A type-specific nested PCR assay established and applied for investigation of HBV genotype and subgenotype in Chinese patients with chronic HBV infection. Virol J (2012) 0.84
Derivation of a myeloid cell-binding adenovirus for gene therapy of inflammation. PLoS One (2012) 0.84
Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed. Mol Cancer Ther (2013) 0.84
Stem cell antigen 1 protects against cardiac hypertrophy and fibrosis after pressure overload. Hypertension (2012) 0.83
Phosphatases and regulation of cell death. Methods Enzymol (2008) 0.83
Adult bone marrow stem cells for cell and gene therapies: implications for greater use. J Cell Biochem Suppl (2002) 0.83
Bcl2 overexpression rescues the hematopoietic stem cell defects in Ku70-deficient mice by restoration of quiescence. Blood (2014) 0.82
A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines. J Gene Med (2003) 0.82
Bone marrow-derived cells exhibiting lung epithelial cell characteristics are enriched in vivo using methylguanine DNA methyltransferase-mediated drug resistance. Stem Cells (2008) 0.82
IL-22 is induced by S100/calgranulin and impairs cholesterol efflux in macrophages by downregulating ABCG1. J Lipid Res (2013) 0.82
Grape seed proanthocyanidins attenuate vascular smooth muscle cell proliferation via blocking phosphatidylinositol 3-kinase-dependent signaling pathways. J Cell Physiol (2010) 0.81
Pyrene excimer nucleic acid probes for biomolecule signaling. J Biomed Nanotechnol (2009) 0.81
Hepatitis B virus basal core promoter mutations A1762T/G1764A are associated with genotype C and a low serum HBsAg level in chronically-infected HBeAg-positive Chinese patients. Antiviral Res (2012) 0.81
Lung tumorigenesis associated with erb-B-2 and erb-B-3 overexpression in human erb-B-3 transgenic mice is enhanced by methylnitrosourea. Oncogene (2002) 0.81
Changes in Glial cell line-derived neurotrophic factor expression in the rostral and caudal stumps of the transected adult rat spinal cord. Neurochem Res (2007) 0.80
Detection of fetal DNA in maternal plasma by microarray coupled with emulsions PCR. Clin Chim Acta (2006) 0.80
Apigenin attenuates neointima formation via suppression of vascular smooth muscle cell phenotypic transformation. J Cell Biochem (2012) 0.79
Imaging stem cell-derived persistent foci after in vivo selection of lentiviral MGMT-P140K transduced murine bone marrow cells. Mol Ther (2011) 0.79
Peritransplant use of ultraviolet-B irradiation (UV-B) therapy is detrimental to allogeneic stem cell transplantation outcome. Biol Blood Marrow Transplant (2006) 0.79
Ag nanoparticle-ZnO nanowire hybrid nanostructures as enhanced and robust antimicrobial textiles via a green chemical approach. Nanotechnology (2014) 0.79
Telomerase inhibition and telomere erosion: a two-pronged strategy in cancer therapy. Trends Pharmacol Sci (2003) 0.79